These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 1327283)

  • 21. Expression of p210bcr/abl by metallothionein promoter induced T-cell leukemia in transgenic mice.
    Honda H; Fujii T; Takatoku M; Mano H; Witte ON; Yazaki Y; Hirai H
    Blood; 1995 May; 85(10):2853-61. PubMed ID: 7537982
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells.
    Danhauser-Riedl S; Warmuth M; Druker BJ; Emmerich B; Hallek M
    Cancer Res; 1996 Aug; 56(15):3589-96. PubMed ID: 8758931
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tyrosine phosphorylation and activation of focal adhesion kinase (p125FAK) by BCR-ABL oncoprotein.
    Gotoh A; Miyazawa K; Ohyashiki K; Tauchi T; Boswell HS; Broxmeyer HE; Toyama K
    Exp Hematol; 1995 Oct; 23(11):1153-9. PubMed ID: 7556524
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Negative regulation of p120GAP GTPase promoting activity by p210bcr/abl: implication for RAS-dependent Philadelphia chromosome positive cell growth.
    Skorski T; Kanakaraj P; Ku DH; Nieborowska-Skorska M; Canaani E; Zon G; Perussia B; Calabretta B
    J Exp Med; 1994 Jun; 179(6):1855-65. PubMed ID: 8195713
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased tyrosine phosphorylation of focal adhesion proteins in myeloid cell lines expressing p210BCR/ABL.
    Salgia R; Brunkhorst B; Pisick E; Li JL; Lo SH; Chen LB; Griffin JD
    Oncogene; 1995 Sep; 11(6):1149-55. PubMed ID: 7566975
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An in vivo and in vitro comparison of the effects of b2-a2 and b3-a2 p210BCR-ABL splice variants on murine 32D cells.
    Guinn BA; Evely RS; Walsh V; Gilkes AF; Burnett AK; Mills KI
    Leuk Lymphoma; 2000 Apr; 37(3-4):393-404. PubMed ID: 10752991
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gene therapy for chronic myelogenous leukemia (CML): a retroviral vector that renders hematopoietic progenitors methotrexate-resistant and CML progenitors functionally normal and nontumorigenic in vivo.
    Zhao RC; McIvor RS; Griffin JD; Verfaillie CM
    Blood; 1997 Dec; 90(12):4687-98. PubMed ID: 9389683
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BCR/ABL-mediated increased expression of multiple known and novel genes that may contribute to the pathogenesis of chronic myelogenous leukemia.
    Salesse S; Verfaillie CM
    Mol Cancer Ther; 2003 Feb; 2(2):173-82. PubMed ID: 12589034
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential effects of tumor promoters on P210bcr-abl expression.
    Li WJ; Smith LA; Kabat KG; Kloetzer WS; Arlinghaus RB
    Hematol Pathol; 1989; 3(3):113-23. PubMed ID: 2687223
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Purging of chronic myelogenous leukemia cells by retrovirally expressed anti-bcr-abl ribozymes with specific cellular compartmentalization.
    Mendoza-Maldonado R; Zentilin L; Fanin R; Giacca M
    Cancer Gene Ther; 2002 Jan; 9(1):71-86. PubMed ID: 11916246
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Growth inhibition of chronic myelogenous leukemia cells by ODN-1, an aptameric inhibitor of p210bcr-abl tyrosine kinase activity.
    Schwartz GN; Liu YQ; Tisdale J; Walshe K; Fowler D; Gress R; Bergan RC
    Antisense Nucleic Acid Drug Dev; 1998 Aug; 8(4):329-39. PubMed ID: 9743470
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Abnormality of c-kit oncoprotein in certain patients with chronic myelogenous leukemia--potential clinical significance.
    Inokuchi K; Yamaguchi H; Tarusawa M; Futaki M; Hanawa H; Tanosaki S; Dan K
    Leukemia; 2002 Feb; 16(2):170-7. PubMed ID: 11840282
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Growth autonomy and lineage switching in BCR-ABL-transduced human cord blood cells depend on different functional domains of BCR-ABL.
    Chalandon Y; Jiang X; Loutet S; Eaves AC; Eaves CJ
    Leukemia; 2004 May; 18(5):1006-12. PubMed ID: 15014528
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.
    Li S; Ilaria RL; Million RP; Daley GQ; Van Etten RA
    J Exp Med; 1999 May; 189(9):1399-412. PubMed ID: 10224280
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
    Beran M; Cao X; Estrov Z; Jeha S; Jin G; O'Brien S; Talpaz M; Arlinghaus RB; Lydon NB; Kantarjian H
    Clin Cancer Res; 1998 Jul; 4(7):1661-72. PubMed ID: 9676840
    [TBL] [Abstract][Full Text] [Related]  

  • 36. p210BCR/ABL-induced alteration of pre-mRNA splicing in primary human CD34+ hematopoietic progenitor cells.
    Salesse S; Dylla SJ; Verfaillie CM
    Leukemia; 2004 Apr; 18(4):727-33. PubMed ID: 14961028
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of P210bcr-abl tyrosine protein kinase activity in various subtypes of Philadelphia chromosome-positive cells from chronic myelogenous leukemia patients.
    Maxwell SA; Kurzrock R; Parsons SJ; Talpaz M; Gallick GE; Kloetzer WS; Arlinghaus RB; Kouttab NM; Keating MJ; Gutterman JU
    Cancer Res; 1987 Mar; 47(6):1731-9. PubMed ID: 2434223
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow.
    Pear WS; Miller JP; Xu L; Pui JC; Soffer B; Quackenbush RC; Pendergast AM; Bronson R; Aster JC; Scott ML; Baltimore D
    Blood; 1998 Nov; 92(10):3780-92. PubMed ID: 9808572
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of the bcr/abl kinase inhibitors AG957 and NSC 680410 on chronic myelogenous leukemia cells in vitro.
    Svingen PA; Tefferi A; Kottke TJ; Kaur G; Narayanan VL; Sausville EA; Kaufmann SH
    Clin Cancer Res; 2000 Jan; 6(1):237-49. PubMed ID: 10656455
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BCR/ABL oncoprotein-targeted antitumor activity of antisense oligodeoxynucleotides complementary to bcr/abl mRNA and herbimycin A, an antagonist of protein tyrosine kinase: inhibitory effects on in vitro growth of Ph1-positive leukemia cells and BCR/ABL oncoprotein-associated transformed cells.
    Okabe M; Kunieda Y; Miyagishima T; Kobayashi M; Kurosawa M; Itaya T; Sakurada K; Miyazaki T
    Leuk Lymphoma; 1993 Jul; 10(4-5):307-16. PubMed ID: 7693103
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.